Skip to main content
Figure 4 | Molecular Neurodegeneration

Figure 4

From: Systemic treatment with liver X receptor agonists raises apolipoprotein E, cholesterol, and amyloid-β peptides in the cerebral spinal fluid of rats

Figure 4

Brain ABCA1 levels were upregulated, while LDLR and VLDLR were slightly reduced by LXR agonist treatment. The brain levels of the LXR target gene ABCA1 and of the apoE receptors LDLR and VLDLR were evaluated in RIPA extracted brain homogenates by Western blot analysis as described in Methods. Equal amounts of supernatant proteins were loaded per lane and actin was used as an additional loading control. A: Representative blots showing ABCA1 levels in the brain of rats treated with vehicle or LXR agonists (left panel). Densitometric analysis of Western blots for ABCA1 (right panel). B: Representative blots showing LDLR and VLDLR steady-state levels in the brain of rats treated with vehicle, T1317, and GW3965 for 10 days (left panel). Densitometric analysis of Western blots for LDLR and VLDLR (right panel). * p < 0.05 compared to vehicle treated controls by ANOVA, N = 4 per group.

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326